SeaBeLife Biotech
Entity

  • SeaBeLife Biotech

    Created in 2019
  • BETA

    Up & running (A)
    Existing signals show a regular activity

  • Social networks

    1,754

  • Activities

    biotech deeptech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    Pl. Georges Teissier, 29680 Roscoff, France

    Roscoff

    France

  • Employees

    Scale: 2-10

    Estimated: 15

  • Engaged corporates

    18
    4 15

  • Added in Motherbase

    1 year, 11 months ago
Description
  • Value proposition

    Solutions to deprogram cell death : A breakthrough innovation to treat and prevent severe pathologies


    We develop small molecules that inhibit regulated necrosis using an original mechanism of action. Regulated necrosis is one of the recently identified pathophysiological factors in many diseases with severe outcomes. The technical, therapeutic and economic potential is major. Our activity focuses on the development of drugs inhibiting regulated necrosis, from the selection of the molecule to the proof of efficacy in the patient. We focus on acute and orphan diseases because preclinical and clinical development is facilitated, allowing proof of concept (POC) to be provided in humans more quickly. We have selected a lead molecule which is currently under preclinical development to treat acute kidney injury (AKI) induced by anti-cancer treatments (such as cisplatin) and to treat acute liver failure (ALF) induced by paracetamol poisoning. We have already identified molecules in our pipeline for which we obtained in cellulo POC in Neurodegenerative diseases and AMD.

    Nécrose régulée, Insuffisance rénale aiguë, Insuffisance hépatique aiguë, Ferroptose, Nécroptose, Intoxication médicamenteuse, néphrotoxicité, hépatotoxicité, maladies neurodégénératives, Paracetamol, and Cisplatine

  • Original language

    Une innovation de rupture pour combattre la mort cellulaire

    SeaBeLife développe des molécules innovantes pour traiter des pathologies sévères impliquant la nécrose régulée. Nos molécules brevetées s'attaquent à la mort cellulaire selon un mécanisme d'action original. Le potentiel thérapeutique et économique est majeur, la nécrose régulée joue un rôle clé dans la pathogenèse de maladies graves: insuffisances hépatique ou rénale aiguë, ischémies cardiaque et cérébrale, maladies neurodégénératives et DMLA.

Corporate interactions BETA
Corporate TypeTweets Articles
France Biotech
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research 		Other

18 Mar 2024


Technopôle Brest-Iroise
Technopôle Brest-Iroise
Business Consulting and Services
Technopôle Brest-Iroise
Business Consulting and Services 		Other

17 Dec 2023


CNRS
CNRS
Research, Research Services
CNRS
Research, Research Services 		Other

15 Dec 2023


Région Bretagne
Région Bretagne
National and local authorities, Government Administration
Région Bretagne
National and local authorities, Government Administration 		Other

30 Apr 2022


Atlanpole Biotherapies
Atlanpole Biotherapies
Public business cluster, Biotechnology, French Cluster, Biotechnology Research
Atlanpole Biotherapies
Public business cluster, Biotechnology, French Cluster, Biotechnology Research 		Other

18 Apr 2024


SATT Ouest Valorisation
SATT Ouest Valorisation
Research, Startup accelerator & VC, Research Services
SATT Ouest Valorisation
Research, Startup accelerator & VC, Research Services 		Other

23 Sep 2024


Ouest-France
Ouest-France
Media, Newspaper Publishing
Ouest-France
Media, Newspaper Publishing 		Other

30 Jun 2022


Bpifrance
Bpifrance
Bank, Banking
Bpifrance
Bank, Banking 		Other

3 Oct 2024


Similar entities
Last news
Show all articles
Social network dynamics